Two institutes at the National Institutes of Health (NIH) have linked arms to go after cancer in a big way. Inspired by the successes of drugs like Gleevec, Herceptin, and Iressa-therapies tar geted to specific changes in the DNA of tumors-the National Cancer Insti tute (NCI) and the National Human Genome Research Institute (NHGRI) are considering an ambitious project to systematically find all genetic altera tions in the major types of cancer. The idea itself is not new as a handful of research groups are already conduct ing similar activities, but the NIH project would bring the scale and speed of discovery to a new level.
The initiative-dubbed the Human Cancer Genome Project (HCGP)-is expected to begin in 2006 with a 3 year pilot project, plans for which will be announced in the next few weeks. Although NCI and NHGRI are provid ing few details prior to the announce ment, the two institutes are expected to solicit applications from different research groups to carry out a vari ety of projects-from collecting tumor samples and sequencing DNA to developing new technologies for ana lyzing the genome. Together these projects will help to unearth new can cer genes and possible drug targets in a discrete set of tumor types. In July 2005, a workshop entitled "Toward a Comprehensive Genomic Analysis of Cancer" was convened by NCI and NHGRI to seek input on the HCGP from the scientific community. Par ticipants agreed that a pilot phase was needed "to attack this enormous problem with multiple projects that use a range of genomic technologies coordinated around the same sam ples," according to a recently released report from the workshop (http://cgap. nci.nih.gov/Info / TCGA _executive_ summary.pdf).
As NCI and NHGRI officials continue to hammer out the precise plan for this pilot phase, genome aficionados say that results from their own stud ies bode well for the proposed HCGP. "In a way, we and other people have already done small pilot projects to show [this approach] is worthwhile," says Victor Velculescu, a researcher at the Johns Hopkins University Kimmel Cancer Center.
For decades, the traditional app roach to identify cancer genes was to handpick likely candidates and then search for mutations within them. But since the completion of the draft human genome sequence in 2000, scientists have had the tools to go after cancer mutations in a more glo bal and systematic way. "The approach of mapping cancer genes has almost been saturated. All low hanging fruits have already been taken," says Richard Wooster. Along with Michael Stratten and Andrew Futreal, Wooster leads the Cancer Genome Project at the Wellcome Trust Sanger Institute in the UK, a project that started in April 2000 and is similar in scope to that planned by the NIH. "We have a good dialogue with the NCI/NHGRI and see this very much as a collaborative effort," says Wooster. "There is a strong history of the NIH working with Sanger. The Sanger sequenced one third of the human genome with the NIH in the public effort."
Scientists of the postgenome era can examine the sequences of thou sands of genes in cancer cells. But because of the expense and techni cal limitations of current sequencing technologies, groups like the Sanger's have, for now, been focusing on spe cific sets of genes rather than attempt ing to go after all of them at once. "We have initially focused on the more likely candidates and then will move to less likely ones and eventually to those genes for which there is no known function," says Wooster.
The Sanger group first opted to home in on genes that act in certain pathways, such as the one involving the infamous ras oncogene, which is mutated in many cancers. The strat egy paid off and in 2002 the group dis covered a gene, called BRAF, that is mutated in 66% of malignant melano mas and at a lower frequency in a wide range of other human cancers. The Sanger is now collaborating with the UK's Institute for Cancer Research, a private research institute based in Lon don, to develop compounds to target this mutation.
A similar approach was independ ently adopted by Johns Hopkins University scientists, who had been working for many years on the genet ics of colon cancer. "We were the first to start looking at gene families in a systematic way, starting with the tyrosine kinases in colon cancer," says Velculescu. "And we made an effort to be comprehensive in our search." In 2004, they discovered PIK3CA, a gene that is mutated in about 30% of all human cancers that had somehow slipped through the fingers of cancer researchers until then.
The kinase family of proteins has been a favorite among cancer gene hunters because these enzymes medi ate the signals that tell a cell to grow or stop growing, processes that go awry in cancer cells. In addition, one of the most successful modern cancer drugs, Gleevec (imatinib mesylate), targets a kinase. "If we can find more kinase mutations, drug companies will already know how to make drugs against them," says Matthew Meyer son of the DanaFarber Cancer Insti tute in Boston.
But researchers at Washington Uni
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NIH is preparing to announce plans for the pilot phase of their proposed Human Cancer Genome Project. This initiative seeks to provide a complete list of the mutations that give rise to cancer. As the speed with which DNA can be sequenced increases and costs decrease, it may be possible in a few years to sequence every gene in every cancer. "It makes absolute sense [to do that eventually]," says Meyerson. "We don't know enough about the process to say which genes could be involved. It could be that noncoding genes or even nontranscribed genes play a role [in cancer]." But for now most researchers say a more selective approach is their best bet. "We don't need every gene sequence. Of course there will be endless arguments about which genes to focus on," says NCI researcher Louis Staudt, who studies lymphoma.
DNA sequencing, although a major component, is only one part of the process of finding cancer mutations. "There are many ways to create a tumor," says Meyerson. "So you need more than one approach to look for alterations in the DNA." Indeed can cers can arise from small mutations in the DNA sequences, changes in the number of copies of specific genes, rearrangements affecting entire chromosomes, and even from tumor viruses that land inside or next to human genes. "The only way to move forward is to do whole genome expression studies and copy number and gene loss assays-which are fairly easy to do-as well as obtaining the sequence information on a subset of human genes," says Staudt. "These approaches need to proceed in paral lel. And then perhaps you also need to look at epigenetic changes." (Epige netic changes-heritable changes in genome function that do not alter the DNA sequence-are also thought to be players in cancer.)
Meyerson's group, in collaboration with that of William Sellers (who has just left his post at the DanaFarber to become head of oncology research for the pharmaceutical giant Novartis), has been using a combination of sequenc ing and "SNP arrays" to find cancer genes. SNP array technology ena bles researchers to look for changes in the number of copies of specific genes across the entire genome. This approach identified a gene that is amplified in melanoma, especially in metastatic disease, showing that genomics can be useful not only to develop therapies but also for deter mining disease prognosis.
In explains Strausberg, who believes that a greater involvement of academic sci entists in the early stages of the drug development process would produce a higher number of hits. "It is important to provide resources to both academic and industrial scientists to help build truly integrated partnerships, quite dis tinct from the traditional view of trans lational research," he adds.
The translation of cancer mutations into cancer therapies is the driving goal of HCGP and similar projects. But some feel the challenge is insurmount able. "If you have a type of tumor that has a stable genome, such as some leukemias, it is possible to cure it by targeting one mutation," says Garth R. Anderson of the Roswell Park Cancer Institute in Buffalo, New York. "But in most adult solid tumors the genome is shot to hell by the time the tumor is found. Even if you find genes like BRAF, the mutation will not be in every cell [in the tumor]."
The large variation in molecular changes from one tumor to another, and even within the same tumor from one cell to another, has long been an obstacle for the development of effec tive therapies. A recent study by the Sanger group provided the first clear demonstration of the vast array of mutations present in cancer cells. The study, which generated over 40 mil lion bases of DNA sequence, identi fied close to 200 mutations in protein kinase genes in lung tumors, indicat ing that many mutated protein kinases may be contributing to lung cancer development but that mutations in any one gene are infrequent. "For some tumors we will find high frequency mutations that will make good drug targets, but many will be a mixture of different low frequency mutations," says Wooster. He adds, however, that this information is still useful "because it informs the drug companies as to what the cancer cell world looks like and how to develop better therapies."
To many cancer specialists, this kind of molecular characterization of tumors is what is needed to move the field forward. "We have already gotten so much mileage out of single molecular abnormalities. This gives us great encouragement to continue with the approach," says Larry Nor ton, a breastoncologist at the Memo rial SloanKettering Cancer Center in New York City and chair of the medical board of The Breast Cancer Research Foundation. "Speaking on behalf of the therapeutic community, I am very sup portive of the [HCGP] initiative. Even if you cannot find therapies it will help us determine prognosis and how to bet ter treat patients," he adds.
The identification of genes that are mutated in cancer is likely to have rip pledown effects in all areas of can cer research. "We cannot predict at this stage all that will come from [the HCGP], but we are excited about it because it might help us with our own work," says Judah Folkman, a researcher at Childrens' Hospital Bos ton, renowned for developing drugs to cut off the blood and nutrient sup ply to tumors. At the moment, no one knows what switches on the abnormal sprouting of blood vessels that feeds tumor growth. "We hope that the can cer genome project will help us find the genes responsible for controlling the switch," says Folkman.
Despite the encouragement expressed by many cancer researchers, most agree that gathering and interpreting massive amounts of sequence data and inte grating it with other kinds of genomics information will not be easy. By one esti mate, the amount of sequencing alone required for the HCGP will be equivalent to doing about 150 Human Genome Projects. Beyond the challenge of obtaining accurate DNA sequence on such a large scale, researchers will have to sift through the hundreds of changes identified in any one set of genes and determine which are specific to cancer and which are normal changes that occur in the DNA of any individual (in other words, polymorphisms).
Ley, Wilson, and colleagues add ressed this problem by comparing each cancer sequence to that of DNA taken from skin cells of the same patientpolymorphisms should be present in both samples whereas cancerspecific changes should be present only in the cancer DNA. "Until massive numbers of genomes are sequenced so that we have a database of all polymor phisms, including rare ones, you have to compare tumor versus germline in the same patient," says Ley. "You need to anticipate this problem and design your experiments to overcome it, even if it will require more effort."
Another potential stumbling block is obtaining cancer DNA that is suf ficiently pure (in other words, free of DNA from normal cells) and in large enough quantities. Scientists who are doing this work say they have spent up to several years finessing tech niques to produce tumor databases with the required quality and quantity of genomic DNA. NCI and NHGRI have each com mitted $50 million to the 3 year pilot project, pending approval from their respective scientific advisory boards and council. But the full price tag of the project, or where the rest of the money will come from, has not yet been revealed. The original proposal for the fullscale HCGP estimated that today the project would cost $12.5 bil lion, but by the time it actually takes off, assuming that sequencing tech nologies continue to become cheaper, the price tag would be about $1.3 bil lion. The potential expense has many scientists worried that the project will take funds away from individual grants at a time of tight funding, but support ers say that is not the intent. "In terms of vision, the scientists who support this project are seeing it as an addi tional resource rather than taking away money from available funds," says Meyerson.
Earlier this year, NCI director Andrew C. von Eschenbach (who in Septem ber took on the additional duties of acting commissioner for the U.S. Food and Drug Administration) set the goal of eliminating suffering and death due to cancer by 2015. Whether projects like the HCGP and other NCI initiatives will bring us closer to that goal remains to be seen. But for now, scientists are cautiously optimistic about what the HCGP gene hunt will produce.
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